ArticleJournal of the National Cancer Institute2014
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Open access · bronzeAbstract read
In one paragraph
Article in Journal of the National Cancer Institute, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).Melanoma research · 2021Trial
- Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants.British journal of clinical pharmacology · 2020Trial
- Trial
- Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.PloS one · 2016Trial
- Precise Molecular Subtyping Reveals Heterogeneity of Lung Adenocarcinoma Based on DNA Methylation.Current medicinal chemistry · 2025Article
- Sequelae of B-Cell Depleting Therapy: An Immunologist's Perspective.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Article
- Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEGEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2024Article
- Identification of m7G-Related miRNA Signatures Associated with Prognosis, Oxidative Stress, and Immune Landscape in Lung Adenocarcinoma.Biomedicines · 2023Article
- MSGNN-DTA: Multi-Scale Topological Feature Fusion Based on Graph Neural Networks for Drug-Target Binding Affinity Prediction.International journal of molecular sciences · 2023Article
- Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines.Investigational new drugs · 2023Article
- Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.Cells · 2022Review
- Prognostic significance of pyroptosis-related factors in lung adenocarcinoma.Journal of thoracic disease · 2022Article
- Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling.Communications biology · 2022Article
- Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?Blood research · 2021Article
- Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.Cancer immunology, immunotherapy : CII · 2021Review
- Review
- Turning liabilities into opportunities: Off-target based drug repurposing in cancer.Seminars in cancer biology · 2021Review
- p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 3 institutions in 1 country.
Wen GaoDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
Michael WangDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
Li WangDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
Haibo LuDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
Shuhong WuDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
Bingbing DaiDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
Zhishuo OuDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
Liang ZhangDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
John V HeymachDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
Kathryn A GoldDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
John MinnaDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
Jack A RothDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
Wayne L HofstetterDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
Stephen G SwisherDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG).
Bingliang FangDepartment of Thoracic and Cardiovascular Surgery (WG, LW, HL, SW, BD, JAR, WLH, SGS, BF) and Department of Lymphoma and Myeloma (MW, ZO, LZ) and Department of Thoracic/Head and Neck Medical Oncology (JVH, KAD), The University of Texas MD Anderson Cancer Center, Houston, TX; Hamon Center for Therapeutic Oncology, The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX (JM); Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (WG). bfang@mdanderson.org.
The University of Texas Southwestern Medical Center · USSouthwestern Medical Center · USThe University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4MNovel CTD inhibitors with synthetic lethality to oncogenic Ras for cancer therapyR01CA124951 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FANG, BINGLIANG · 2010 to 2013
$1.2MNCI NIH HHS CA-016672NCI NIH HHS CA070907NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA124951
Abstract
Ibrutinib, which irreversibly inhibits Bruton tyrosine kinase, was evaluated for antitumor activity in a panel of non-small cell lung cancer (NSCLC) cell lines and found to selectively inhibit growth of NSCLC cells carrying mutations in the epidermal growth factor receptor (EGFR) gene, including T790M mutant and erlotinib-resistant H1975 cells. Ibrutinib induced dose-dependent inhibition of phosphor-EGFR at both Y1068 and Y1173 sites, suggesting ibrutinib functions as an EGFR inhibitor. Survival was analyzed by Kaplan-Meier estimation and log-rank test. All statistical tests were two-sided. In vivo study showed that ibrutinib statistically significantly suppressed H1975 tumor growth and prolonged survival of the tumor bearing mice (n = 5 per group). The mean survival times for solvent- and erlotinib-treated mice were both 17.8 days (95% confidence interval [CI] = 14.3 to 21.3 days), while the mean survival time for ibrutinib-treated mice was 29.8 days (95% CI = 26.0 to 33.6 days, P = .008). Our results indicate that ibrutinib could be a candidate drug for treatment of EGFR-mutant NSCLC, including erlotinib-resistant tumors.
Indexed as
MutationAdenineAnimalsAntineoplastic AgentsBlotting, WesternCarcinoma, Non-Small-Cell LungCell Line, TumorCell SurvivalDose-Response Relationship, DrugDrug Resistance, NeoplasmErbB ReceptorsErlotinib HydrochlorideHumansKaplan-Meier EstimateLung NeoplasmsMethionineAdenineAntineoplastic AgentsEGFR protein, humanErbB ReceptorsErlotinib HydrochlorideibrutinibMethioninePiperidinesPyrazolesPyrimidinesQuinazolinesThreonine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.